Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...